EssilorLuxottica SA — Financial Overview, Stock Price, Market Cap

Financial Performance

5Y price score: 66

10Y return: 103.4%

DATE RANGE:

EUR Per
Share

Earnings per share
Free cash flow per share
Stock price

By default your notes are visible only to you.

186.8

52-week range

323.8

196.4

Your model inputs


Required return / cost of capital
FCFF terminal growth rate

Your fair value & Margin of safety

To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

Forecast:

Valuation

Free Cash Flow Yield

FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per share

4.1 %

Dividend Yield TTM

2 %

Market cap

90,970.7

Price / Earnings TTM

P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per share

39.4

Price / Book TTM

2.3

PEG TTM

Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rate

(13.5)

Earnings growth and return

LTM

5YR

10YR

Total return (price & dividends)

(17.2) %

54 %

103.4 %

Free cash flow per share growth

11.2 %

54.6 %

102.5 %

Earnings per share growth

(2.9) %

2,521.1 %

42.3 %

Founded: 2,018

Employees: 193,693

Business Summary: EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, Europe, Latin America, Asia, Oceania, and Africa. It operates in five segments: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses and Readers. The Wholesale segment engages in the manufacture and wholesale distribution of luxury and sports eyewear. The Retail segment retails luxury and sports eyewear. The Lenses and Optical Instruments segment offers lenses and small equipment, including Varilux progressive lenses; Crizal antireflective, anti-smudge, and antistatic lenses; Transitions photochromic lenses; Eyezen lenses for users of computers, tablets, smartphones, and other connected devices; Xperio polarized sun lenses; and Nikon and Kodak corrective lens brands. It also provides lens edging and mounting instruments for opticians and prescription laboratories; optometry instruments for eye care professionals, schools, occupational medicine centers, military, and other institutions; and Transitions Signature Gen 8 photochromic lens, as well as develops solutions for online sales of optical products. The Equipment segment offers digital surfacing machines and lens coating machines to prescription laboratories, integrated optical chains, and lens manufacturers. The Sunglasses and Readers segment provides non-prescription sunglasses and reading glasses under the Foster Grant, Gargoyles, Magnivision, Corinne McCormack, Monkey Monkey, Ryders Eyewear, and SolarShield brands; Reebok, Steve Madden, Betsey Johnson, Nine West, Dockers, French Connection, Ironman, Rawlings, Bodyglove, Panama Jack, Marvel, and Disney; Bolon, Molsion, Qina, and Prosun brands; and Mujosh and Aojo brands. It has a network of 490 prescription laboratories and edging-mounting facilities. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.

Financials

all figures in EUR Millions except per share data

Periods:

View:

Forecast:

Averages

based on historical growth rates (CAGR) and average margins for last 10 or max, available and up to 10 years.

Analysts

Average Revenue and Net Income forecast estimates from analysts who cover the stock.

Custom

you can edit default forecast based on averages or analysts consensus and use it to calculate fair value based on your assumptions.

ㅤ

Actual

10 year gagr

Estimated

Projected

Fiscal

FISCAL PERIOD END DATES

01Earnings per share

Diluted EPS

02FCF per share

03Dividends per share

Adjusted for splits

04Dividends payout, %

05Revenue

06ㅤ% Change

07Net Income

08ㅤ% Margin

09CFO

10ㅤ% Of revenue

11CAPEX

12ㅤ% Change

13FCFF

Free Cash Flow to the Firm = Cash Flows from Operating Activities (09) – Capital Expenditures (11)

14Total assets

15ㅤ% Change

16Total liabilities

17ㅤ% Of assets

18Shareholders Equity

19Net Debt

20Shares Outstanding

Diluted Weighted-average Shares Outstanding

21ㅤ% Change

22ROA

23ROE

24Interest coverage

25Dividend Yield

26P/E Ratio

27Stock price range

28Market Cap

End of Period Market Cap

29FCF Yield

30Average stock price

31 CEO

Fair Value Reference Estimate

Increase
Decrease
Total


Required return / cost of capital
FCFF terminal growth rate
Free cash flow forecast
Terminal value
ㅤPV breakdown
Enterprise value / PV of FCF
ㅤPlus / (Less): Net Debt
ㅤLess: preferred stock
ㅤLess: minority interest
Market cap
ㅤNumber of shares
Price per share

Latest Earnings Call Takeaways

2025 Q4 (Feb 11, 2026)

1) Strategic Transformation and Leadership Vision - EssilorLuxottica is undergoing a significant transformation from a traditional optical company to a med-tech and data-driven group, aiming to shape the future of health and human performance. - The company recorded a revenue growth of 18% in Q4 2025 and 11% for the full year, marking a historic double-digit growth. - The introduction of AI glasses has been pivotal, with over 7 million units sold in 2025, driven by strong brand performance from Ray-Ban and Oakley. - The leadership emphasizes the importance of integrating AI glasses into a broader med-tech vision, expanding into areas such as predictive medicine and early detection of health conditions.

2) Financial Performance and Segment Results - Full-year revenue reached EUR 28.5 billion, with adjusted operating profit at EUR 4.5 billion, despite a EUR 300 million headwind from U.S. tariffs and adverse exchange rates. - Q4 performance highlighted a 24% growth in North America, 16% in EMEA, and 12% in Asia Pacific, with Latin America showing an 8% increase. - The company achieved a record free cash flow of EUR 2.8 billion, up EUR 400 million from the previous year.

Metric	Q4 2025 Growth	Full Year 2025 Growth
Revenue (constant currency)	18%	11%
Operating Profit	-	EUR 4.5 billion
Free Cash Flow	EUR 2.8 billion	-

3) Challenges and Headwinds - The company faced challenges from U.S. tariffs, which impacted gross margins, alongside adverse foreign exchange rates. - The gross margin decreased by 260 basis points year-over-year, attributed mainly to tariffs and the higher contribution of AI glasses to revenue. - Ongoing foreign exchange headwinds are expected to persist into 2026, with a projected impact of about 6 percentage points on results.

4) Operational and Product Plans - EssilorLuxottica plans to expand its capabilities in AI glasses, with a focus on increasing production capacity in partnership with Meta. - The myopia management portfolio grew by 22% in 2025, with Stellest lenses gaining traction, particularly in the U.S. market, where reimbursement coverage is improving. - The company is committed to enhancing its logistics and distribution networks, leveraging both physical retail and e-commerce to drive growth.

5) Guidance and Outlook - The company is optimistic about its long-term outlook, expecting aligned growth of revenues and operating profits over the next five years. - There is a focus on expanding the AI glasses portfolio and enhancing the Stellest product line in the U.S. market. - The transcript lacks specific guidance figures for 2026, particularly regarding expected margin impacts and detailed projections for wearables.

Bottom line: EssilorLuxottica is poised for continued growth driven by its strategic transformation into a med-tech leader, bolstered by strong financial performance and innovative product offerings, despite facing headwinds from tariffs and foreign exchange fluctuations. Shareholders can expect a promising trajectory as the company expands its market presence and product capabilities.